

Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit C α

JÜRGEN GÖTZ*[†], ALPHONSE PROBST[‡], ELISABETH EHLER[§], BRIAN HEMMINGS[¶], AND WILFRIED KUES*^{||}

*Institut für Molekularbiologie, Abteilung I, Universität Zürich, Höggerberg, 8093 Zurich, Switzerland; [‡]Institut für Neuropathologie, Universität Basel, 4003 Basel, Switzerland; [§]Institut für Zellbiologie, Eidgenössische Technische Hochschule Zürich, Höggerberg, 8093 Zurich, Switzerland; and [¶]Friedrich-Miescher-Institut, P.O. Box, 4002 Basel, Switzerland

Communicated by Charles Weissmann, University of Zurich, Zurich, Switzerland, July 8, 1998 (received for review March 9, 1998)

ABSTRACT Protein phosphatase 2A (PP2A) is a multi-meric enzyme, containing a catalytic subunit complexed with two regulatory subunits. The catalytic subunit PP2A C is encoded by two distinct and unlinked genes, termed C α and C β . The specific function of these two catalytic subunits is unknown. To address the possible redundancy between PP2A and related phosphatases as well as between C α and C β , the C α subunit gene was deleted by homologous recombination. Homozygous null mutant mice are embryonically lethal, demonstrating that the C α subunit gene is an essential gene. As PP2A exerts a range of cellular functions including cell cycle regulation and cell fate determination, we were surprised to find that these embryos develop normally until postimplantation, around embryonic day 5.5/6.0. While no C α protein is expressed, we find comparable expression levels of PP2A C at a time when the embryo is degenerating. Despite a 97% amino acid identity, C β cannot completely compensate for the absence of C α . Degenerated embryos can be recovered even at embryonic day 13.5, indicating that although embryonic tissue is still capable of proliferating, normal differentiation is significantly impaired. While the primary germ layers ectoderm and endoderm are formed, mesoderm is not formed in degenerating embryos.

Protein phosphorylation is probably the major regulatory mechanism employed by eukaryotic cells at the protein level (1, 2). The protein phosphatase 2A (PP2A) family of holoenzymes has been implicated in many different facets of cellular function (3, 4). Besides regulating metabolic enzymes, PP2A appears to modulate many proteins involved in signal transduction, including cell surface receptor molecules, cytosolic protein kinases, and transcription factors. The modification of proteins important for cell-cycle regulation, cell transformation, and cell fate determination affects essential processes of every cell.

Although much is known about the structure of PP2A enzymes, the regulatory features that control their activity remain to be elucidated. Many different trimeric holoenzymes of PP2A have been purified and evaluated with regard to substrate specificity and subunit composition (3, 4). All holoenzymes have in common a catalytic subunit of 36 kDa (PR36) and a 65-kDa regulatory subunit (PR65). These "core" subunits associate with a range of regulatory subunits (PR55, PR61, PR72) to form different heterotrimers.

The catalytic subunit has been cloned from a variety of species. From mammals cDNA clones encoding two different subunits, termed C α and C β , were isolated. Both consist of 309 amino acids with a predicted molecular mass of 35.6 kDa. They are 97% identical, with 7 of 8 different residues located within

the first 30 amino acids. The specific function of these two subunits is unknown. Analysis of the expression of the two isoforms from different porcine and rat tissues showed that the highest levels of the transcripts encoding both isoforms occur in the brain, whereas the levels in other tissues analyzed were about 1/10 as high. In all cases the C α transcripts were about 10-fold more abundant than the C β transcripts (5). Interestingly, increased amounts of C β transcripts were reported in chemically induced rat liver tumors. Increased levels of the C α subunit were found in several transformed cell lines (6, 7). Furthermore, solid tumors or cell lines transfected with *retI*, *Ki-ras*, or *c-raf* oncogenes have elevated catalytic subunit transcript levels (8).

To dissect the functions of the two catalytic subunits in mice, a gene targeting approach was chosen. We created a mouse strain deficient in PP2A C α . This approach allows us to address the possible redundancy between PP2A and related phosphatases as well as between C α and C β .

MATERIALS AND METHODS

Cloning. PP2A C α genomic sequences were cloned from an isogenic λ Gem11 (Promega) phage genomic library prepared from AB1 [129/Sv(ev)] embryonic stem (ES) cell DNA (9). Eight phage clones were isolated by hybridization with a murine cDNA probe, and their restriction map was established. Analysis of these clones reveals that the gene organization is similar to that in humans, where the C α locus spans approximately 30 kb and is composed of seven coding exons with the six introns intervening at identical locations (10). A 9-kb *Bam*HI fragment containing exon 1 was subcloned into the Bluescript vector (Stratagene). Sequencing from exon 1 into the promoter region revealed a striking sequence conservation between rat (10) and mouse. Since the deletion of 0.5 kb immediately upstream of the transcription start site of the rat C α gene abolishes expression in a chloramphenicol acetyltransferase (CAT) assay (11), for a complete knockout of C α a targeting construct (ZH13) was generated encompassing 8.1 kb of genomic sequence. An internal 0.9-kb *Stu*I/*Sma*I fragment including more than 0.5 kb of the promoter, exon 1, as well as approximately 0.3 kb of intron 1 were replaced by a neomycin-resistance gene constitutively transcribed from a phosphoglycerate kinase promoter inserted in opposite transcriptional orientation (12). In this 2-kb cassette (13), the neomycin-resistance gene (inserted in antisense orientation) is followed by the 360-bp UMS *Sal*I-*Nco*I sequence, reported to mediate transcriptional termination (14) in the sense orientation. A herpes simplex virus thymidine kinase (HSV TK) gene

Abbreviations: PP2A, protein phosphatase 2A; C α , PP2A catalytic subunit C α ; C β , PP2A catalytic subunit C β ; ES cell, embryonic stem cell; neo, neomycin-resistance gene cassette; *En*, embryonic day *n*.

[†]To whom reprint requests should be addressed. e-mail: goetz@molbio1.unizh.ch.

^{||}Present address: Institut für Tierzucht und Tierverhalten, Mariensee, 31535 Neustadt, Germany.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

© 1998 by The National Academy of Sciences 0027-8424/98/9512370-6\$2.00/0 PNAS is available online at www.pnas.org.

was added at the 3' end of the $C\alpha$ sequence to allow counter selection (12). The targeting vector was then linearized with *Sac*II in the Bluescript backbone for electroporation.

ES Cell Culture and Selection. GS1 [129/Sv(ev)] ES cells were electroporated with the linearized vector as described (15). Among the 192 G418-resistant clones that were expanded, 6 had undergone specific homologous recombination as demonstrated by PCR using primers P3 (5'-ATTCG-CAGCGCATCGCCTTCTATCGCC-3') from the 3' end of the neo cassette and WO-1 (5'-GATATTCCTACTACAAAC-CAGAG-3') corresponding to a genomic sequence 5' from the targeting vector. These clones were shown to be heterozygous for the interrupted $C\alpha$ gene as revealed by Southern blot analysis (data not shown) and used to generate chimeric animals by injecting them into blastocysts from C57BL/6 mice. Crossing of chimeras with wild-type C57BL/6 females allowed germ-line transmission for two clones.

Genotyping by PCR, Southern, and Northern Blotting. Genomic DNA was prepared as described (15). A 0.9-kb *Bam*HI/*Bgl*II fragment not present on the targeting construct was used as flanking probe for Southern blot analysis. Upon digesting genomic DNA with *Bam*HI, a 9-kb wild-type allele and a 10.1-kb mutant allele were detected. The existence of a single integration site at the targeted locus was verified by using a neo probe, giving a single 10.1-kb fragment (not shown). Extracts for PCR analysis were prepared from tail biopsies, dissected embryos, scraped paraffin sections, or blastocysts as described (15, 16).

Primers P3 and WO-6 (5'-GCTGTTGGACTAGCGCT-TAGG-3') generated a 450-bp PCR fragment revealing the homologously recombined allele, and primers WO-6 and O-198 (5'-AGCTCCTTGGTGAACAACCTTC-3') generated a 650-bp fragment diagnostic of the wild-type PP2A $C\alpha$ allele. The following primers were used for the PCR analysis of fixed tissue and scraped-off sections: Primers O-210 (5'-CAAGAT-GGATTGCACGCAGG-3') and O-211 (5'-GCTTCAGTGA-CAACGTCGAG-3') are internal to the neomycin gene and generate a 250-bp fragment, primers O-212 (5'-GGCATCAT-GGACGAGAAGTTG-3') and O-213 (5'-TTCTCGCAGAG-GCTCTTGAC-3') are internal to the $C\alpha$ exon I and generate a 107-bp wild-type product.

Total RNA was extracted from brain as described (15), electrophoresed on a 0.9% formaldehyde gel with 20 μ g of total RNA per lane. After separation, the RNA was stained with ethidium bromide to visualize the 28S and 18S rRNA bands for normalization, followed by a transfer to a Hybond N⁺ membrane (Amersham). ³²P-labeled $C\alpha$ exon 6 (5'-ACTTAAGAGTGTGCTCAAGT-3') and exon 7 (5'-GACATGTGGCTCGCCTCTAC-3') specific oligonucleotides in the antisense orientation were used as probes for hybridization.

Histology, Immunohistochemistry, and RNA *in Situ* Hybridization. Embryos within their decidua were fixed in 4% formaldehyde buffered in PBS (formalin) overnight at room temperature, dehydrated in graded alcohols, embedded in paraffin, sectioned sagittally (2- to 3- μ m sections), and stained with hematoxylin and eosin. Immunohistochemical detection of PP2A C on sections used Promega rabbit antiserum V598A (directed against a C-terminal peptide shared by $C\alpha$ and $C\beta$) and a biotinylated anti-rabbit secondary antiserum (Vector Laboratories). Detection of $C\beta$ used rabbit antiserum 15 [directed against amino acids 22–31 of $C\beta$, an amino acid stretch showing a high degree of sequence diversity between $C\alpha$ and $C\beta$ (17, 18)]. Antiserum 45 (anti- $C\alpha$) (17, 18) did not work on paraffin-embedded sections. Staining was revealed by the ABC method, with the appropriate Vectastain kit (Vector Laboratories) using diaminobenzidine (and 5% NiCl₂) as substrate. Specificity of staining was confirmed by concurrent processing of tissue sections where the primary antibody had been omitted.

For whole-mount immunohistochemistry embryos and blastocysts [embryonic day 3.5 (E3.5)] were fixed in Dent's fixative (19), dehydrated, and permeabilized in PBS/2% milk powder/0.1% Triton X-100. Antisera V598A (anti- $C\alpha$ and β) and 45 [anti- $C\alpha$; directed against the first 20 amino acids of $C\alpha$, an amino acid stretch showing a high degree of sequence diversity between $C\alpha$ and $C\beta$ (17, 18)] were used, followed by a horseradish peroxidase-conjugated anti-rabbit IgG antiserum (Dako), using diaminobenzidine as a substrate. Specificity of staining was confirmed by including controls from which the primary antibody had been omitted.

Whole mount RNA *in situ* hybridization was done following standard protocols (15, 20). Antisense RNA probes were made for brachyury (21) and goosecoid (22) transcripts as described (23), and a digoxigenin RNA labeling kit (Boehringer Mannheim) was used.

RESULTS AND DISCUSSION

Inactivation of PP2A $C\alpha$. To investigate the role of the PP2A catalytic subunit $C\alpha$ during embryonic development, we generated a null mutant by using gene targeting in ES cells. A targeting vector was constructed in which the promoter, exon I, and part of intron I were replaced by a neomycin-resistance cassette (Fig. 1*a*). Among the 192 G418-resistant clones that were expanded, 6 had undergone specific homologous recombination as demonstrated by PCR and Southern blot analysis (data not shown). These clones were used to generate chimeric animals by injecting them into blastocysts from C57BL/6 mice. Crossing of chimeras with wild-type C57BL/6 females allowed germ-line transmission for two clones. Adult heterozygous mice derived from both clones were overtly normal. $C\alpha$ protein levels and phosphatase activity were not reduced in heterozygous mice compared with wild-type controls (data not shown).

Embryonic Lethality of Homozygous Knockout Mice. Of more than 350 progeny derived from heterozygous crosses, none were homozygous null ($-/-$), demonstrating that the $C\alpha$ subunit is essential for the development of viable offspring (Fig. 1*b*). We obtained identical results with mice generated from two independent ES cell clones. Analysis of brain RNA extracted from wild-type and heterozygous mice by using antisense oligonucleotide probes specific for exon 6 and exon 7 of $C\alpha$ reveals that no aberrant mRNA is transcribed from the mutant allele (Fig. 1*c*). To investigate the time of the presumptive embryonic lethality, we determined the genotype of individual embryos by using PCR (Fig. 1*d*). Homozygous null blastocysts (E3.5) appeared morphologically normal and were identified at a ratio that was not significantly different from the expected Mendelian distribution (data not shown).

Histological examination revealed that all E5.5 embryos from two heterozygous crosses displayed normal morphology, whereas approximately 25% of all E6.5 and E7.0 embryos from four heterozygous crosses were degenerated and smaller (compare Fig. 2*a* with *b* and *2 c* with *d*) than heterozygous or wild-type embryos, which were all normal. Both normal and degenerated ($-/-$) embryos exhibit defined layers of cells of extra-embryonic and embryonic endoderm, as well as extra-embryonic and embryonic ectoderm, but degenerated embryos (Fig. 2*b* and *d*) are consistently smaller, and embryonic ectoderm seems to be more degenerated than extra-embryonic ectoderm (Fig. 2*d*). Taken together, these data show that the initial development of $-/-$ embryos is not different from that of heterozygous or wild-type embryos. Null ($-/-$) blastocysts display a normal morphology of both inner cell mass and trophoctoderm. The embryos implant properly, and both the extra-embryonic and embryonic portion of the egg cylinder differentiate to develop the two primary germ layers, ectoderm and endoderm. It seems likely that even a proamniotic cavity can form in the absence of $C\alpha$, as some of the degenerating embryos form a cavity. At E6.5 all $-/-$ embryos show signs




Fig. 1. PP2A $C\alpha$ gene targeting and genotyping. (a) Homologous recombination of the $C\alpha$ genomic locus resulted in the replacement of 0.5 kb of the promoter, the entire exon I, and 0.3 kb of intron I sequences by the neomycin cassette. The neomycin cassette was flanked by 1 kb and 6 kb of genomic $C\alpha$ sequences, respectively. The transcriptional orientation of the $C\alpha$ gene is indicated by an arrow. BHI, *Bam*HI; Bgl, *Bgl*II. The diagnostic primers WO-1 and P3 used to detect homologous recombination are indicated by arrowheads. (b) Southern blot analysis of viable offspring obtained from heterozygous matings. Genomic DNA was digested with *Bam*HI (BHI) and probed with a flanking *Bam*HI/*Bgl*II fragment (shown in a). Viable offspring were either heterozygous (+/-) or wild-type (+/+) as shown by the presence of a 9-kb wild-type and 10.1-kb mutant band, respectively. (c) Northern blot analysis of RNA obtained from wild-type (lane 1) and heterozygous (lane 2) brain, using a $C\alpha$ -specific antisense oligonucleotide probe. (d) Genotyping of dissected E8.5 embryos obtained after heterozygous matings. All degenerated embryos (D1–D3) were genotypically -/- as shown by the presence of a 450-bp mutant PCR product and the absence of a 650-bp wild-type PCR product; all phenotypically normal embryos (N1–N7) were either +/+ or +/- as shown by the presence of a 650-bp wild-type PCR product. Two controls are shown for the two PCRs: For the wild-type PCR, targeting plasmid ZH13 was included as a negative control (C1) and wild-type tail lysate (C2) as a positive control. As controls for the presence of the mutant allele, wild-type (C1) and heterozygous (C2) tail lysates were included.

of degeneration, which affects all germ layers, but is most pronounced in embryonic ectoderm, leading to a block in subsequent differentiation steps (see below).

PP2A $C\alpha$ Expression in Normal and Degenerated Embryos. E7.5 embryos were dissected from the decidua and analyzed by whole mount immunohistochemistry using rabbit antiserum 45, which is specific for $C\alpha$ and does not cross-react with $C\beta$ (17, 18). $C\alpha$ was present in embryos with apparently normal morphology with a relatively uniform expression pattern (Fig. 3a). In contrast, $C\alpha$ could not be detected in morphologically abnormal embryos (Fig. 3b), which displayed several phenotypes. Some had a proamniotic cavity and others formed an amorphous cell mass of different sizes. Genotyping revealed that the abnormal embryos were homozygous null mutants. These embryos ceased proper development shortly after implantation, demonstrating clearly that neither $C\beta$ nor catalytic subunits of other phosphatases can compensate for the absence of $C\alpha$ at this stage of development.

Partial Redundancy of the PP2A Catalytic Subunits. Despite the fact that PP2A $C\alpha$ seems to be implicated in cell cycle regulation (1, 3, 24), homozygous null mutant embryos can survive until E5.5/E6.0. A first possible explanation for this finding is that prior to E6.5, $C\alpha$ is not essential and its function can be assumed by other related phosphatase catalytic subunits such as $C\beta$. Alternatively, maternal stocks of $C\alpha$ could persist until after implantation and be sufficient for the initial embryonic cell divisions. To discriminate between these possibil-

ities, we analyzed dissected E7.5 embryos by whole mount immunohistochemistry using rabbit antiserum V598A, which is directed against an epitope common to $C\alpha$ and $C\beta$. Previous experiments have shown that in different cell lines (10) and adult tissues (5), and also during *Xenopus* embryogenesis (25), $C\alpha$ mRNA is generally far more abundant than $C\beta$. However, expression levels in the mouse embryo have not been described. We found that both normal and degenerated (-/-) embryos expressed PP2A C (α and β) at comparable levels (Fig. 3c and d). This finding was confirmed by immunohistochemical analysis of sections from E6.5 decidua using antiserum V598A, which showed similar staining intensities for both normal and degenerated embryos (Fig. 4a and b). Controls were included in which the primary antiserum had been omitted (Fig. 4c). In addition, serial sections were stained with antiserum 15, which is directed against a $C\beta$ -specific epitope. Normal and degenerated embryos show comparable staining intensities (Fig. 4d and e). The genotypes were determined by PCR analysis from embryonic tissue of serial sections. Our findings suggest that before E6.5 PP2A $C\alpha$ is not essential and may be only weakly expressed in comparison to $C\beta$. At and beyond E6.5, PP2A $C\beta$ may not compensate for the lack of $C\alpha$ either because sufficient amounts of C protein are not provided because of the weak promoter of $C\beta$ (10) or because $C\beta$ cannot dephosphorylate all substrates of $C\alpha$. Comparable expression levels of C in normal and degenerating embryos at the time of onset of degeneration would argue for the latter.




FIG. 2. Morphology of embryos obtained from heterozygous crosses. Serial sagittal sections were made from embryonic day E6.5 (*a* and *b*) and E7.0 (*c* and *d*) deciduae (29). The genotype of these embryos was determined by PCR analysis of serial sections from which embryonic tissue was scraped off. Sections were stained with hematoxylin and eosin. Normal (*a* and *c*) and degenerated (*b* and *d*) embryos exhibit defined layers of cells of extra-embryonic (exEn) and embryonic (eEn) endoderm, and extra-embryonic (exEc) and embryonic (eEc) ectoderm. Degenerated embryos (*b* and *d*) are smaller and some of them are amorphous. Embryonic ectoderm seems to be more degenerated than extra-embryonic ectoderm (*d*). Parietal endoderm (pEn), visceral (vEn) endoderm, and the ectoplacental cone (EPC) are indicated. (Scale bar = 50 μ m.)

The second possibility, that in both wild-type and mutant embryos maternal stocks of $C\alpha$ may persist, is difficult to assess because wild-type blastocysts reveal only very weak $C\alpha$ staining. During normal mouse development, most maternal mRNAs are destroyed upon activation of the zygotic genome, although maternal stores of some mRNAs have been shown to persist until the blastocyst stage (26). It is unlikely that material stocks of $C\alpha$ mRNA do persist, since in the 3'-untranslated region, there are five copies of the AUUUA motif, which is thought to mediate rapid mRNA turnover (27). At least in *Xenopus*, high levels of both $C\alpha$ and $C\beta$ transcripts decrease rapidly during the meiotic and first mitotic embryonic cell divisions (25).

Proliferation and Differentiation of the Degenerating Embryo. Embryos were also dissected from the decidua at later stages of embryonic development. Genotypically homozygous null embryonic cell masses could be recovered as late as E13.5 at a ratio of approximately 0.25 (data not shown). This finding suggests that the embryo or part of it is still capable of proliferating, but that normal differentiation is significantly impaired. The presence of these cell masses is surprising, as degenerating embryos are normally rapidly resorbed. Disruption of the cyclin A2 gene (28), for example, results in embryonic death around E5.5, with no residual embryonic material found at E8.5. Likewise, disruption of the β -catenin




FIG. 3. Whole mount immunohistochemistry of dissected E7.5 embryos obtained from heterozygous matings. The genotype of dissected embryos was determined by PCR. (*a* and *b*) Dissected embryos were stained with antiserum 45 (17, 18), which is specific for $C\alpha$ and does not cross-react with $C\beta$. In morphologically normal embryos (*a*) $C\alpha$ is expressed almost uniformly, whereas morphologically abnormal ($-/-$) embryos (*b*) do not express $C\alpha$. (*c* and *d*) However, when an antiserum is employed that is directed against an epitope shared between $C\alpha$ and $C\beta$, normal (*c*) and degenerated (*d*) embryos are stained equally well. Some of the degenerated embryos show a (proamniotic) cavity (*d*), the borders of which are indicated by arrowheads. (Scale bar = 50 μ m.)

gene (16) leads to death at around E7.0 with almost complete resorption at E9.0. It can be speculated that PP2A may regulate signal transduction pathways involved in apoptosis and growth control.

As mutant embryos start to degenerate at or shortly before the primitive streak stage, when under normal conditions gastrulation is initiated (29) and cells in the embryonic ectoderm are induced to form mesoderm (E6.5), we dissected E7.0 embryos resulting from heterozygous crosses and analyzed them by RNA *in situ* hybridization. RNA probes for two mesodermal markers were employed. Brachyury transcripts (Fig. 5*b* and *c*) (21) and goosecoid transcripts (data not shown) (22) could be detected in the primitive streak area of all phenotypically normal embryos; however, they were not found in mutant embryos. When wild-type E6.5 embryos were dissected, the pattern of Brachyury staining (Fig. 5*a*) revealed that mesoderm formation had already been initiated. The size of these wild-type embryos is comparable to that of degenerated embryos dissected at E7.0. Mutant embryos were analyzed at E7.0 and not at E6.5 as we wanted to control for a possible developmental delay of mutant embryos. As Brachyury is a very early mesodermal marker with low levels of transcript present in cells juxtaposed to the embryonic-extra-embryonic junction already the day before the primitive streak can be recognized (30), our data suggest that $C\alpha$ may be required for the onset of gastrulation and that this function can neither be taken over by other phosphatases nor by PP2A containing $C\beta$ as catalytic subunit. We therefore expect that transgenic overexpression of $C\beta$ would not rescue the $C\alpha$ knockout phenotype.




FIG. 4. PP2A C (*a–c*) and C β (*d* and *e*) expression of embryos obtained from heterozygous crosses. Serial sagittal sections were made from E6.5 deciduae (29). The genotype of these embryos was determined by PCR analysis of serial sections from which embryonic tissue was scraped off. (*a* and *b*) Sections were stained with antiserum V598A, which is directed against an epitope common to C α and C β . The degenerated embryo (*b*) exhibits the same staining intensity for C as the normal embryo (*a*). (*Inset c*) A control is included where the primary antiserum has been omitted. (*d* and *e*) Sections were stained with antiserum 15, which has been raised with a C β -specific peptide. Normal (*d*) and degenerated (*e*) embryos exhibit comparable staining intensities. (Scale bar = 50 μ m.)

Conclusions. Our results show that PP2A C α is an essential gene. Despite a proposed role of PP2A in cell cycle regulation, null mutant embryos die only at around day E6.5. Presence of embryonic cell masses as late as E13.5 implies that PP2A may be involved in signal transduction pathways controlling apoptosis.

Our data suggest that C α and C β exert different functions in the developing embryo. C β expression is sufficient to keep

at least part of the embryo proliferating, but C α expression is required for proper cell fate determination. The amino acid sequences of C α and C β are 97% identical, but 7 of 8 amino acid differences are clustered in the first 30 amino acid residues, which are encoded by exon I. Therefore, it has been speculated (10) that these differences are significant and that exon I encodes sequences important for regulation and substrate specificity. PP2A C α may be involved in early signaling




FIG. 5. RNA whole mount *in situ* hybridization of embryos analyzed for the expression of mesodermal markers (23) by using digoxigenin-labeled antisense probes for goosecoid (data not shown) and Brachyury. (*a–c*) Embryos were dissected at E6.5 (*a*) and E7.0 (*b* and *c*). Transcripts (purple staining) are present in morphologically normal embryos (*a* and *c*) but are undetectable in degenerated embryos (*b*). (Scale bar = 50 μ m.)

cascades such as the wnt pathway, which controls the epithelial–mesenchymal transition during vertebrate development. Potential substrates of PP2A during embryonic development include the phosphoproteins β -catenin and glycogen synthase kinase 3 β , which participate in wingless/wnt signaling (31). The expression of the β -catenin-associated cell adhesion molecule E-cadherin, for example, is dramatically reduced in $-/-$ embryos (data not shown).

Further analysis of PP2A function will come from null mutants of the different isoforms of the regulatory subunits, which could reveal more subtle phenotypes related to PP2A function.

We thank G. Stark and C. Mistl for excellent technical assistance; G. Horan and R. Behringer for Brachyury and gooseoid plasmids; G. Stark for ES cell line GS1; the members of the Weissmann laboratory for constant support; and H. Naim and R. Kemler for critically reading the manuscript. This work was supported by the Canton of Zürich and a grant from Sandoz Ltd. (Novartis) to J.G.

- Sontag E., Numbhakdi-Craig, V., Bloom, G. S. & Mumby, M. C. (1995) *J. Cell. Biol.* **128**, 1131–1144.
- Snaith, H. A., Armstrong, C. G., Guo, Y., Kaiser, K. & Cohen, P. T. W. (1996) *J. Cell Sci.* **109**, 3001–3012.
- Cohen, P. (1989) *Annu. Rev. Biochem.* **58**, 453–508.
- Shenolikar, S. & Nairn, A. C. (1991) in *Advances in Second Messengers and Phosphoprotein Research*, eds. Greengard, P. & Robinson, G. A. (Raven, New York), Vol. 25, pp. 1–121.
- Khew-Goodall, Y. & Hemmings, B. (1988) *FEBS Lett.* **238**, 265–268.
- Kitagawa, Y., Sakai, R., Tahira, T., Tsuda, H., Ito, N., Sugimura, T. & Nagao M. (1988) *Biochem. Biophys. Res. Commun.* **157**, 821–827.
- Kitagawa, Y., Tahira, T., Ikeda, I., Kikuchi, K., Tsuiki, S., Sugimura, T. & Nagao, M. (1988) *Biochim. Biophys. Acta* **951**, 123–129.
- Nagao, M., Sakai, R., Kitagawa, Y., Ikeda, I., Sasaki, K., Shima, H. & Sugimura, T. (1990) in *Genetic Basis for Carcinogenesis: Tumor Suppressor Genes and Oncogenes*, ed. Knudson, A. G. (Taylor & Francis, London), pp. 177–184.
- Müller, U., Cristina, N., Li, Z.-W., Wolfer, D. P., Lipp, H.-P., Rülcke, T., Brandner, S., Aguzzi, A. & Weissmann, C. (1994) *Cell* **79**, 755–765.
- Khew-Goodall, Y., Mayer, R. E., Maurer, F., Stone, S. R. & Hemmings, B. (1991) *Biochemistry* **30**, 89–97.
- Kitagawa, Y., Shima, H., Sasaki, K. & Nagao, M. (1991) *Biochim. Biophys. Acta* **1089**, 339–344.
- Thomas, K. R. & Capecchi, M. R. (1987) *Cell* **51**, 503–512.
- Ruffner, H., Reis, L. F. L., Näf, D. & Weissmann, C. (1993) *Proc. Natl. Acad. Sci. USA* **90**, 11503–11507.
- Heard, J. M., Herbomel, P., Ott, M. O., Mottura, R. A., Weiss, M. & Yaniv, M. (1987) *Mol. Cell. Biol.* **7**, 2425–2434.
- Hogan, B., Beddington, R., Constantini, F. & Lacy, E., eds. (1994) *Manipulating the Mouse Embryo* (Cold Spring Harbor Lab. Press, Plainview, NY), 2nd Ed.
- Haegel, H., Larue, L., Ohsugi, M., Fedorov, L., Herrenknecht, K. & Kemler, R. (1995) *Development (Cambridge, U.K.)* **121**, 3529–3537.
- Turowski, P., Fernandez, A., Favre, B., Lamb, N. J. C. & Hemmings, B. A. (1995) *J. Cell. Biol.* **129**, 397–410.
- Andjelkovic, A., Zolnierowicz, S., Van Hoof, C., Goris, J. & Hemmings, B. A. (1996) *EMBO J.* **15**, 7156–7167.
- Dent, J. A., Polson, A. G. & Klymkowsky, M. W. (1989) *Development (Cambridge, U.K.)* **105**, 61–74.
- Wilkinson, D. G. (1992) in *In Situ Hybridization, A Practical Approach*, ed. Wilkinson, D. G. (IRL Press, Oxford), pp. 75–83.
- Herrmann, B. G. (1991) *Development (Cambridge, U.K.)* **113**, 913–917.
- Blum, M., Gaunt, S. J., Cho, K. W., Blumberg, B., Bittner, D. & De Robertis, E. M. (1992) *Cell* **69**, 1097–1106.
- Shawlot, W. & Behringer, R. R. (1995) *Nature (London)* **374**, 425–430.
- Virshup, D. M., Kauffman, M. G. & Kelly, T. J. (1989) *EMBO J.* **8**, 3891–3898.
- Van Hoof, C., Ingels, F., Cayla, X., Stevens, I., Merlevede, W. & Goris, J. (1995) *Biochem. Biophys. Res. Commun.* **215**, 666–673.
- Flach, G., Johnson, M. H., Braude, P. R., Taylor, R. A. & Bolton, V. N. (1982) *EMBO J.* **1**, 681–686.
- Wera, S., Fernandez, A., Lamb, N. J., Hemmings-Mieszczak, M., Mayer-Jaekel, R. E. & Hemmings, B. A. (1995) *J. Biol. Chem.* **270**, 21374–21381.
- Murphy, M., Stinnakre, M.-G., Senamaud-Beaufort, C., Winston, N. J., Sweeney, C., Kubelka, M., Carrington, M., Bréchet, C. & Sobczak-Thépot, J. (1997) *Nat. Genet.* **15**, 83–86.
- Downs, K. M. & Davies, T. (1993) *Development (Cambridge, U.K.)* **118**, 1255–1266.
- Thomas, P. & Beddington, R. (1996) *Curr. Biol.* **6**, 1487–1496.
- Peifer, M., Pai, L.-M. & Casey, M. (1994) *Dev. Biol.* **166**, 543–556.